Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspire Biopharma HoldingsASBP -3.99%8 EV-to-FCF is -0.77 as of Jul. 28, 2026. GuruFocus rates ASBP with a GF Score™ of 8/100. The stock has 2 warning signs investors should review. Among 341 Biotechnology companies, Aspire Biopharma Holdings ranks worse than 293254.84% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Aspire Biopharma Holdings's Enterprise Value is $4.77 Mil.
Aspire Biopharma Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.21 Mil. Therefore, Aspire Biopharma Holdings's EV-to-FCF for today is -0.77.
The historical rank and industry rank for Aspire Biopharma Holdings's EV-to-FCF or its related term are showing as below:
ASBP'
s EV-to-FCF Range Over the Past 10 Years
Min: -7.27 Med: -1.77 Max: 0.58
Current: -0.77
During the past 4 years, the highest EV-to-FCF of Aspire Biopharma Holdings was 0.58. The lowest was -7.27. And the median was -1.77.
ASBP's EV-to-FCF is ranked worse than 100% of 341
companies
in the Biotechnology industry
Industry Median: 14.64
vs ASBP: -0.77
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aspire Biopharma Holdings's PE Ratio (TTM) for today is calculated as:
Aspire Biopharma Holdings's share price for today is $7.05.
Aspire Biopharma Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-156.541.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Aspire Biopharma Holdings EV-to-FCF Related Terms
Aspire Biopharma Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aspire Biopharma Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspire Biopharma Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aspire Biopharma Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Aspire Biopharma Holdings's EV-to-FCF falls into.
Aspire Biopharma Holdings's current Enterprise Value is $4.77 Mil.
Aspire Biopharma Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspire Biopharma Holdings (ASBP) has a EV-to-FCF of -0.77 as of Jul. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Aspire Biopharma Holdings and its competitors. According to the industry distribution chart, Aspire Biopharma Holdings ranks #999999 out of 341 companies in the Biotechnology industry.
Is Aspire Biopharma Holdings' EV-to-FCF too high?
Aspire Biopharma Holdings' current EV-to-FCF is -0.77. Based on the distribution chart, Aspire Biopharma Holdings ranks #999999 out of 341 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aspire Biopharma Holdings has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Aspire Biopharma Holdings' EV-to-FCF compare to VTGN and CRIS?
According to the Biotechnology industry distribution chart, Aspire Biopharma Holdings ranks #999999 out of 341 companies for EV-to-FCF. This places Aspire Biopharma Holdings in the lower half of its industry. The industry median EV-to-FCF is 14.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.64, based on 341 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Aspire Biopharma Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspire Biopharma Holdings's current EV-to-FCF is -0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspire Biopharma Holdings stock overvalued right now?
Aspire Biopharma Holdings (ASBP) has a current EV-to-FCF of -0.77. The current EV-to-FCF is -0.77. Aspire Biopharma Holdings' overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Aspire Biopharma Holdings (ASBP), the current EV-to-FCF is -0.77 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
8GF Score
Get the complete analysis for ASBP
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASBP has been successfully added to your 
